Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · IEX Real-Time Price · USD
0.657
-0.051 (-7.26%)
Apr 25, 2024, 10:19 AM EDT - Market open
Company Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.
Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 135 |
| CEO | Faheem Hasnain |
Contact Details
Address: 3013 Science Park San Diego, California 92121 United States | |
| Phone | (858) 922-0718 |
| Website | gossamerbio.com |
Stock Details
| Ticker Symbol | GOSS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001728117 |
| CUSIP Number | 38341P102 |
| ISIN Number | US38341P1021 |
| Employer ID | 47-5461709 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Faheem Hasnain | Co-Founder, Chief Executive Officer, President and Chairman |
| Bryan Giraudo | Chief Operating Officer and Chief Financial Officer |
| Dr. Richard Aranda M.D. | Chief Medical Officer |
| Christian Waage | Executive Vice President of Technical Operations and Administration |
| Jeff Boerneke | General Counsel and Secretary |
| Deanna Weber | Senior Vice President of Human Resources |
| Mario Orlando | Senior Vice President of Commercial New Product Planning |
| Caryn L. Peterson | Executive Vice President of Regulatory Affairs |
| Matt Cravets | Senior Vice President of Biometrics |
| Dr. Lisa Elizabeth Nolan Ph.D. | MD and President of Gossamer Bio Ireland |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2024 | 8-K | Current Report |
| Mar 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 5, 2024 | 10-K | Annual Report |
| Mar 5, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |